Showing 191 results
- https://www.novartis.com/news/novartis-condemns-terrorist-actions-against-people-israel-and-loss-innocent-lives
- https://www.novartis.com/news/novartis-statement-filing-inflation-reduction-act-lawsuit
- https://www.novartis.com/news/novartis-statement-about-entresto-sacubitrilvalsartan-selection-medicare-drug-price-negotiation-program
- https://www.novartis.com/news/european-commission-ec-adopts-decision-endorsing-chmp-recommendation-revoke-conditional-marketing-authorization-adakveo-crizanlizumab
- https://www.novartis.com/news/novartis-statement-collaboration-and-license-agreement-tislelizumab-beigene-ltd
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
- https://www.novartis.com/news/novartis-provides-support-moroccan-earthquake-victims
- https://www.novartis.com/news/novartis-giving-volunteering-wins-accps-2023-corporate-social-impact-team-year-award
- https://www.novartis.com/news/gt005-ppy988-development-program-geographic-atrophy
- https://www.novartis.com/news/study-suggests-there-may-be-two-stages-fatal-lung-disease-covid-19
NIBR translational immunologists and academic colleagues observe two distinct molecular patterns of disease progression in lung tissue samples.
- https://www.novartis.com/news/choice-responsibility-reimagining-how-we-work
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 20
- › Next page